Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci 2016 Sep 08;17(9) PMID: 27618026 PMCID: PMC5037783

Pubmed ID

27618026

DOI

10.3390/ijms17091506

Abstract

Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clonal expansion in the bone marrow (BM). It is the second-most common hematologic malignancy. Despite significant advances in therapeutic strategies, MM remains a predominantly incurable disease emphasizing the need for the development of new treatment regimens. Immunotherapy is a promising treatment modality to circumvent challenges in the management of MM. Many novel immunotherapy strategies, such as adoptive cell therapy and monoclonal antibodies, are currently under investigation in clinical trials, with some already demonstrating a positive impact on patient survival. In this review, we will summarize the current standards of care and discuss major new approaches in immunotherapy for MM.

Author List

Al-Hujaily EM, Oldham RA, Hari P, Medin JA

Authors

Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin
Jeffrey A. Medin PhD Professor in the Pediatrics department at Medical College of Wisconsin




Scopus

2-s2.0-84987722672   10 Citations

MESH terms used to index this publication - Major topics in bold

Animals
Antibodies, Monoclonal
Humans
Immunotherapy, Adoptive
Multiple Myeloma
jenkins-FCD Prod-332 f92a19b0ec5e8e1eff783fac390ec127e367c2b5